Our proposal represents an integrated approach to determining the cardiovascular and metabolic effects of strawberry consumption in adults who have high risk for cardiometabolic disease.
The current proposal aims to fill some of these important research gaps with regard the dose and time-course of strawberry consumption in a population where dietary intervention may of particular benefit for both primary and secondary prevention of cardiovascular and metabolic disease. Participants will participate in a double blind, placebo-controlled, randomized crossover trial. Following a 10-day run-in where no berries are consumed, participants will be randomized via Latin-square design, to three different daily strawberry powder conditions for 4-weeks at a time, with a 7 day washout between conditions.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
48
Participants will drink a strawberry beverage with active ingredients once a day during the 4-week intervention period.
Participants will drink a strawberry placebo beverage once a day during the 4-week intervention period.
Participants will drink a mixed strawberry beverage with active ingredients and placebo once a day during the 4-week intervention period.
Lafene Health Center
Manhattan, Kansas, United States
Change in plasma lipids
Total cholesterol (TC), LDL-c , VLDL-c, HDL-c , triglycerides (TG) from blood sample in a fasted state and following consumption of a meal
Time frame: Week 0, 4, 5, 9, 10, and 14
Change in glucose and insulin response
Glucose, insulin, and c-peptide obtained from blood sample in a fasted state and in response to a meal
Time frame: Week 0, 4, 5, 9, 10, and 14
Change in oxidixed LDL
Obtained from blood sample in a fasted state and following consumption of a meal
Time frame: Week 0, 4, 5, 9, 10, and 14
Change in homeostatic model assessment for insulin resistance
Calculated from fasting glucose and insulin values
Time frame: Week 0, 4, 5, 9, 10, and 14
Change in inflammation
hs-CRP and IL-6 will be assessed in the fasted state from plasma
Time frame: Week 0, 4, 5, 9, 10, and 14
Change in arterial stiffness
Determined via changes in carotid artery stiffness calculated from simultaneous measurements of carotid artery diameter and pressure-waveforms
Time frame: Week 0, 4, 5, 9, 10, and 14
Change in blood pressure (resting and 24-hr)
Evaluated via automated sphygmomanometer. 24-hr ambulatory blood pressure is taken at 20-30 minute intervals over a 24hr period while the individual goes about their normal activities and while sleeping.
Time frame: Week 0, 4, 5, 9, 10, and 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in endothelial function
Flow mediated dilation (FMD) assessed via a non-invasive 2D Doppler ultrasound following a 5-min period of arterial occlusion.
Time frame: Week 0, 4, 5, 9, 10, and 14